

## **Perfusion Imaging to Select Patients with Large Ischemic Core for Mechanical Thrombectomy**

Basile Kerleroux, Kevin Janot, Cyril Dargazanli, Dimitri Daly-Eraya, Wagih Ben-Hassen, François Zhu, Benjamin Gory, Jean François Hak, Charline Perot, Lili Detraz, et al.

► **To cite this version:**

Basile Kerleroux, Kevin Janot, Cyril Dargazanli, Dimitri Daly-Eraya, Wagih Ben-Hassen, et al.. Perfusion Imaging to Select Patients with Large Ischemic Core for Mechanical Thrombectomy. *Journal of Stroke, Korean Stroke Society*, 2020, 22 (2), pp.225-233. 10.5853/jos.2019.02908 . inserm-02971228

**HAL Id: inserm-02971228**

**<https://www.hal.inserm.fr/inserm-02971228>**

Submitted on 19 Oct 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Perfusion Imaging to Select Patients with Large Ischemic Core for Mechanical Thrombectomy

Basile Kerleroux,<sup>a</sup> Kevin Janot,<sup>a</sup> Cyril Dargazanli,<sup>b</sup> Dimitri Daly-Eraya,<sup>b</sup> Wagih Ben-Hassen,<sup>c</sup> François Zhu,<sup>d</sup> Benjamin Gory,<sup>d</sup> Jean François Hak,<sup>e</sup> Charline Perot,<sup>f</sup> Lili Detraz,<sup>g</sup> Romain Bourcier,<sup>g</sup> Aymeric Rouchaud,<sup>h</sup> Géraud Forestier,<sup>h</sup> Joseph Benzakoun,<sup>c</sup> Gaultier Marnat,<sup>i</sup> Florent Gariel,<sup>i</sup> Pasquale Mordasini,<sup>j</sup> Johannes Kaesmacher,<sup>j</sup> Grégoire Boulouis,<sup>c</sup> on Behalf of the JENI Research Collaborative

<sup>a</sup>Diagnostic and Therapeutic Neuroradiology, CHRU de Tours, Tours, France

<sup>b</sup>Department of Interventional Neuroradiology, University Hospital Center of Montpellier, Gui de Chauliac Hospital, Montpellier, France

<sup>c</sup>Centre Hospitalier Sainte Anne, Neuroradiology Department, Paris University, INSERM U1266, Psychiatry and Neurosciences Institute of Paris, Paris, France

<sup>d</sup>University Hospital of Nancy, Department of Diagnostic and Therapeutic Neuroradiology, INSERM U1254, Nancy, France

<sup>e</sup>Department of Diagnostic and Interventional Neuroradiology, Timone Hospital, Aix Marseille University, Marseille, France

<sup>f</sup>Neurology Department, Timone Hospital, Aix Marseille University, Marseille, France

<sup>g</sup>Department of Diagnostic and Interventional Neuroradiology, Guillaume et René Laennec University Hospital, Nantes, France

<sup>h</sup>Department of Interventional Neuroradiology, Dupuytren University Hospital, Limoges, France

<sup>i</sup>Department of Diagnostic and Interventional Neuroradiology, Pellegrin Hospital-University Hospital of Bordeaux, Bordeaux, France

<sup>j</sup>Institute of Diagnostic, Interventional and Pediatric Radiology and Institute of Diagnostic and Interventional Neuroradiology, University Hospital Bern, Inselspital, University of Bern, Bern, Switzerland

**Background and Purpose** Patients with acute ischemic stroke, proximal vessel occlusion and a large ischemic core at presentation are commonly not considered for mechanical thrombectomy (MT). We tested the hypothesis that in patients with baseline large infarct cores, identification of remaining penumbral tissue using perfusion imaging would translate to better outcomes after MT.

**Methods** This was a multicenter, retrospective, core lab adjudicated, cohort study of adult patients with proximal vessel occlusion, a large ischemic core volume (diffusion weighted imaging volume  $\geq 70$  mL), with pre-treatment magnetic resonance imaging perfusion, treated with MT (2015 to 2018) or medical care alone (controls; before 2015). Primary outcome measure was 3-month favorable outcome (defined as a modified Rankin Scale of 0–3). Core perfusion mismatch ratio (CPMR) was defined as the volume of critically hypo-perfused tissue ( $T_{max} > 6$  seconds) divided by the core volume. Multivariable logistic regression models were used to determine factors that were independently associated with clinical outcomes. Outputs are displayed as adjusted odds ratio (aOR) and 95% confidence interval (CI).

**Results** A total of 172 patients were included (MT  $n=130$ ; Control  $n=42$ ; mean age  $69.0 \pm 15.4$  years; 36% females). Mean core-volume and CPMR were  $102.3 \pm 36.7$  and  $1.8 \pm 0.7$  mL, respectively. As hypothesized, receiving MT was associated with increased probability of favorable outcome and functional independence, as CPMR increased, a difference becoming statistically significant above a mismatch-ratio of 1.72. Similarly, receiving MT was also associated with favorable outcome in the subgroup of 74 patients with CPMR  $> 1.7$  (aOR, 8.12;

Correspondence: Grégoire Boulouis  
Centre Hospitalier Sainte Anne, Neuro-radiology Department, Paris University, INSERM U1266, Psychiatry and Neurosciences Institute of Paris, 1 rue Cabanis, 75014 Paris, France  
Tel: +33-145658574  
Fax: +33-145658574  
E-mail: [gregoireboulouis@gmail.com](mailto:gregoireboulouis@gmail.com)

Received: October 25, 2019

Revised: March 30, 2020

Accepted: April 28, 2020

95% CI, 1.24 to 53.11;  $P=0.028$ ). Overall (prior to stratification by CPMR) 73 (42.4%) patients had a favorable outcome at 3 months, with no difference amongst groups.

**Conclusions** In patients currently deemed ineligible for MT due to large infarct ischemic cores at baseline, CPMR identifies a subgroup strongly benefiting from MT. Prospective studies are warranted.

**Keywords** Acute stroke; Ischemic stroke; Thrombectomy; Endovascular treatment; Perfusion imaging

## Introduction

In recent years, mechanical thrombectomy (MT) has demonstrated its compelling efficacy in reducing mortality and functional dependence for patients with acute ischemic stroke (AIS) due to anterior proximal vessel occlusion (PVO).<sup>1,2</sup> Patients with an unfavorable imaging profile at baseline, assessed using magnetic resonance imaging (MRI) diffusion weighted imaging (DWI) volume core ( $\geq 70$  mL),<sup>1</sup> or the computed tomography (CT)-based-Alberta Stroke Program Early CT score (ASPECTS)  $< 6$ , were excluded in four of the seven randomized clinical trials that validated MT in AIS-PVO,<sup>3</sup> precluding to draw strong conclusions in this subgroup. Hence they are typically not offered MT in clinical practice,<sup>1</sup> despite converging evidence suggesting a benefit of MT despite large ischemic core (LIC), with almost 25% of patients experiencing favorable functional outcome after MT.<sup>3-9</sup>

Perfusion imaging is used in the diagnostic work up of AIS to identify hypo-perfused yet not infarcted (e.g., 'at-risk' or 'salvageable') brain tissue,<sup>10</sup> and to estimate the core perfusion mismatch ratio (CPMR).<sup>2</sup> Nonetheless, perfusion data remain very scarce in patients with LIC before MT, while they are critically needed to pragmatically design future randomized trials, and better select patients for MT until then.

We hypothesized that perfusion imaging may enhance the effective selection of AIS-PVO patients with LIC by determining those likeliest to benefit from revascularization and tested this hypothesis in a cohort study using data from a multicenter cohort, by comparing the rates of favorable functional outcome, symptomatic intracerebral hemorrhage (sICH), and case-fatality in patients with DWI assessed baseline LIC ( $> 70$  mL) and perfusion who received MT versus patients who were treated with intravenous thrombolysis only. The hypothesis driving this analysis was that in patients with baseline large infarct cores, identification of significant remaining penumbral tissue, as assessed using CPMR, would translate to better outcomes after MT.

## Methods

### Study design

The study was a multicenter, core-lab adjudicated, observational retrospective cohort study. The "Jeunes en Neuroradiologie Interventionnelle Research Collaborative" (JENI-RC), is a recently launched trainee-led research network.<sup>11</sup> Local JENI-RC members were asked to provide de-identified data for patients with DWI ASPECTs 0-6 otherwise meeting study inclusion criteria (see below). Case report form items included demographics, relevant past medical history, sICH, and 3-month functional outcome. Imaging data were centralized by the internal core lab, for central assessment. Nine academic centers contributed data (eight in France, and one in Switzerland). This report was prepared according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement.<sup>12</sup>

### Ethics

As for all non-interventional retrospective studies of de-identified data in France, written informed consent was waived and a commitment to compliance (reference methodology CPMR-3) was filed to the French National Information Science and Liberties Commission prior to data centralization, in respect to the General Data Protection Regulation.

### Inclusion criteria

In the MT group, we included consecutive adult patients with AIS after 2015 if they had an occlusion of the intracranial internal carotid artery or of the M1 segment of the middle cerebral artery; had a large pretreatment ischemic core volume defined as 70 mL or more on magnetic resonance-DWI as assessed centrally; had no preexisting handicap as defined by a modified Rankin Scale (mRS) of 2 or higher; underwent MT; and if pre-treatment MR-T2\* perfusion sequence had been performed. The control group was constituted by retrospectively querying the prospective intravenous tissue plasminogen activator (tPA) stroke data base at a single university hospital, to identify patients treated before MT related guidelines in 2015

who met the same criteria but did not receive MT due to guidelines compliance.

### Imaging analysis and mismatch definition

The post-processing and images interpretation were performed centrally after complete de-identification, by an internal core-lab (B.K. and G.B.), blinded to clinical data.

Ischemic core volumes (DWI volume) were calculated using Olea-Sphere version 3.0 software (Olea Medical, La Ciotat, France), by the semi-automated segmentation of brain tissue ipsilateral to the occlusion with apparent diffusion coefficient of  $0.6 \times 10^{-3}$  mm<sup>2</sup>/sec or less. Perfusion maps were generated using the Olea-Sphere version 3.0 software then used to calculate critically hypo-perfused brain tissue, with an inferior threshold set, according to recent literature,<sup>13</sup> at T max >6 seconds. As in previous large studies investigating core penumbral mismatch,<sup>14,15</sup> we defined penumbral tissue as the volume of critically hypo-perfused tissue minus the DWI volume. Similarly, we defined the CPMR, as the volume of critically hypo-perfused tissue divided by the DWI volume, and defined a target mismatch as patients with a CPMR of 1.8 or above.

### Assessment criteria

The primary endpoint was functional outcome assessed at 3 months, using the mRS, with a favorable outcome defined by a score of 3 or less, taking into account the inherent severity of AIS with baseline LIC, and in line with recent literature. Secondary end points included functional independence defined as mRS of 0–2. Ninety days mortality, and the rate of symptomatic intracerebral hemorrhage within 7 days (according to European Cooperative Acute Stroke Study [ECASS] II criteria).<sup>16</sup> Substantial reperfusion was defined as a modified Thrombolysis in Cerebral Infarction score of 2B, 2C, or 3.<sup>17</sup>

### Statistical analysis

Baseline characteristics of patients has been compared between MT group and control group. Continuous variables were summarized using mean±standard deviation or median (interquartile range) where appropriate, and discrete variables were summarized using counts (percentages). Chi-square test, Fisher-exact test, t-test, Mann-Whitney test were used as appropriate for the univariate analysis, with a  $P < 0.05$  as the threshold for statistical significance.


Clinical outcomes were compared between MT group and control group. First, multivariable logistic regression models were used to determine factors that were independently associated with clinical outcomes. Variables associated with the outcome in univariate analysis ( $P \leq 0.1$ ) were entered into nomi-

nal logistic models, with a prespecified adjustment for age, infarct core, and CPMR. Backward elimination was then used to remove non-significant variables ( $P > 0.05$ ). The adjusted odds ratios (aOR) and 95% confidence interval (CI) of having favorable outcome (model 1) and functional independence (model 2) were reported. Then, a sensitivity analysis was performed to assess for changes in the results in patients with a predefined CPMR cutoff of 1.8, as was reported in previous cornerstone studies analyzing the pertinence of CMPR in AIS-PVO patients.<sup>13,18</sup> Finally, a shift analysis of mRS score (of 0–6 points) based on the proportional odds model has been performed. All analyses were done using JMP Pro 14 (Institute Inc., Cary, NC, USA) software. Where needed, we derived 95% CI by bootstrapping (5,000 occurrences) statistical results.<sup>18</sup>

## Results

### Study population

Between January 2015 and July 2018, in the MT group a total of 971 patients with AIS-PVO and ASPECTs 0–6 were screened for inclusion. After applying inclusion criteria, 168 patients were evaluated by the core lab, of which 130 were finally included and analyzed in the MT group. Before 2015, a total of 154 patients with DWI-ASPECTs 0–6 were screened for inclusion in the control group, and 42 met study criteria (Figure 1). A total of 172 were finally included in the present analysis (36% females, mean age  $69.0 \pm 15.4$  years) (Table 1 for baseline clinical-imaging characteristics). Patients in the MT group were



**Figure 1.** Flow chart. DWI, diffusion weighted imaging; ASPECTs, Alberta Stroke Program Early Computed Tomography Score; PWI, perfusion weighted imaging; MT, mechanical thrombectomy.

more frequently females (41% vs. 21%,  $P=0.03$ ), less frequently received intravenous tPA (48.5% vs. 100%,  $P<0.01$ ), were more frequently referred from an outside primary stroke center hospital (25.4% vs. 0%,  $P<0.01$ ), were younger ( $66.2\pm 14.9$  years-old vs.  $77.7\pm 13.5$ ,  $P<0.01$ ). They did not differ otherwise in terms of baseline clinical parameters, notably for delay between onset and qualifying imaging ( $P=0.58$ ) and occlusion site ( $P=0.82$ ). Substantial recanalization was achieved in 111/140 patients in the MT group (79.3%).

### Core and penumbra

Mean core DWI volume was  $102.3\pm 36.7$  mL and did not differ between groups. The volume of critically hypo-perfused tissue was larger in the MT group (mean  $180.8\pm 72.4$  mL vs.  $145.5\pm 52.5$  mL,  $P<0.01$ ), which consequently demonstrated larger penumbral volumes (mean  $76.8\pm 63.7$  mL vs.  $48.8\text{mL}\pm 40.9$  mL,  $P<0.01$ ) as well as higher CPMRS (mean  $1.8\pm 0.7$  vs.  $1.5\pm 0.5$ ,  $P<0.01$ ). A total

of 90 (52%), 65 (38%), and 53 (31%) patients had CPMRS above 1.6, 1.8, and 2.0 respectively (Supplementary Figure 1, in the supplemental material for detailed CPMR distribution in the cohort).

### Outcomes

#### Functional outcomes

At 3 months, 73 (42.4%) patients had a favorable functional outcome (mRS 0–3), with no difference amongst groups prior to stratification by CPMR (43.1% in the MT vs. 40.5,  $P=0.86$ ). Forty-one patients (23.8%) were functionally independent and 54 (31.4%) were deceased ( $P=1.000$ ) (Table 2). Unfavorable outcome was associated with higher age, higher baseline NIHSS, history of hypertension, and diabetes mellitus (Supplementary Table 1).

Independent of, as well as within, treatment groups both larger core and larger penumbral volumes were associated with

**Table 1.** Baseline characteristics of included patients

Variable	All (n=172)	Control (n=42)	MT (n=130)	P
Age (yr)	69.0±15.4	77.7±13.5	66.2±15	<0.001
Female sex	62 (36)	9 (21.4)	53 (40.8)	0.029
Dyslipidemia	69 (40.1)	18 (42.9)	51 (39.2)	0.718
Diabetes mellitus	26 (15.1)	7 (16.7)	19 (14.6)	0.811
Tobacco use (current or past)	56 (32.6)	14 (33.3)	42 (32.3)	1.000
Hypertension	97 (56.4)	24 (57.1)	73 (56.2)	1.000
NIHSS	18.5±4.5	18±5.1	18.7±4.2	0.435
Left sided stroke	75 (43.6)	16 (38.1)	59 (45.4)	0.476
iv tPA	105 (61)	42 (100)	63 (48.5)	<0.001
Drip and ship	33 (19.2)	0 (0)	33 (25.4)	<0.001
ICA occlusion	31 (18)	7 (16.7)	24 (18.5)	0.269
Delay till imaging (min)	161.3±129	152.7±108.5	164±135.2	0.583
Volume T max <6 sec (mL)	172.2±69.6	145.5±52.5	180.8±72.4	<0.001
Mismatch ratio	1.8±0.7	1.5±0.5	1.8±0.7	<0.001
Core volume (mL)	102.3±36.7	96.7±33	104±37.7	0.233

Values are presented as mean±standard deviation or number (%).

MT, mechanical thrombectomy; NIHSS, National Institute of Health Stroke Scale; iv tPA, intravenous tissue plasminogen activator; ICA, internal carotid artery.

**Table 2.** Outcome of included patients

Variable	All (n=172)	Control (n=42)	MT (n=130)	P
Substantial recanalization	-	-	111 (79.3)	
90-day, mRS 0–2	41 (23.8)	11 (26.2)	30 (23.1)	0.684
90-day, mRS 0–3	73 (42.4)	17 (40.5)	56 (43.1)	0.857
90-day, mortality	54/172 (31.4)	13 (30.9)	41 (31.5)	1
sICH	31/161 (19.3)	5/35 (14.3)	26/126 (20.26)	0.483

Values are presented as number (%).

MT, mechanical thrombectomy; mRS, modified Rankin Scale; sICH, symptomatic intra-cranial hemorrhage.

poor functional outcome in univariable analysis ( $185 \pm 67.9$  mL in patients with mRS 4–6 vs.  $154 \pm 68.4$  mL in those with mRS 0–3,  $P < 0.01$ ; and  $76 \pm 59$  vs.  $67 \pm 60$ ,  $P = 0.04$ ) (Figure 2).


In the entire population, there was no difference in favorable outcome between treatment groups ( $P = 0.68$ ) (Table 1). After adjusting for age, hypertension, diabetes, core volume, CPMR, delay to imaging, intravenous tPA before MT, and occlusion site, there was a significant interaction between MT effect and CPMR in both models (Model 1: aOR, 0.29;  $P = 0.008$ ; and Model 2: aOR, 0.4;  $P = 0.047$ ), indicating an increasing benefit of MT as CPMR increases (Table 3). In the same model, with mismatch ratio dichotomized as a nominal variable (below or above 1.8) the odds ratio of the interaction term between treatment arm

and mismatch ratio ( $> 1.8$ ), was 0.42 (95% CI, 0 to 0.82;  $P = 0.02$ ).

Analyzing the probability for favorable outcome in the fully adjusted model plotted against CPMR, we showed that receiving MT (vs. not receiving MT) was associated with increased probability of favorable outcome and functional independence, as CPMR increased, a difference becoming statistically significant above a CPMR of 1.72 for favorable outcome, and above 1.93 for functional independence (Figure 3).

As a sensitivity analysis, when stratifying by CPMR; in the sample of 65 patients with a CPMR of 1.8 or above, after adjusting for group specific outcome predictors (age, core volume, intravenous tPA, and CPMR), receiving MT was associated with a significant increase in the rate of favorable outcome (aOR, 9.99; 95% CI, 9.99 to infinite). Similarly, in the subgroup of 74 patients for which CPMR exceeded 1.7 (42% of favorable outcome in the MT group vs. 20% in the control group,  $P = 0.031$ ; receiving MT was associated with a significantly increased rate of favorable outcome) (aOR, 8.12; 95% CI, 1.24 to 53.11,  $P = 0.028$ ). Using ordinal regression, receiving MT was associated with overall favorable shift in mRS distribution (common risk ratio, 1.83; 95% CI, 1.01 to 3.44;  $P = 0.049$ ) (Figure 4).

Finally, when restricting the sample to patients in the MT group, we found substantial recanalization to be associated with significantly higher odds of favorable outcome and of 3 months functional independence, in fully adjusted models (aOR, 53.7; 95% CI, 5.0 to 573;  $P < 0.001$ ; and aOR infinite,  $P < 0.001$ , respectively). Lower age ( $P < 0.001$ ), lower mismatch ratio ( $P = 0.03$ ), and lower core volume ( $P < 0.001$ ) were also associated with higher odds of favorable outcome, but the interaction between CPMR and substantial recanalization only tended towards significance ( $P = 0.058$ ).




**Figure 2.** Modified Rankin Scale at 3 months and initial diffusion weighted imaging (DWI) core volume and mismatch ratio per group.

**Table 3.** Multivariable models for outcome


Variable	For favorable outcome			For functional independence		
	aOR	95% CI	P	aOR	95% CI	P
Age (yr)	0.95	0.92–0.98	<0.001	0.97	0.94–1.00	0.048
Diabetes	0.33	0.11–1.02	0.049	0.36	0.09–1.45	0.015
Hypertension	0.85	0.39–1.82	0.673	0.79	0.33–1.88	0.591
iv tPA	1.74	0.76–3.96	0.188	2.10	0.83–5.36	0.119
Delay till imaging (min)	1.00	1.00–1.00	0.934	1.00	1.00–1.00	0.754
ICA occlusion	0.75	0.28–2.00	0.572	0.59	0.18–1.94	0.391
Volume core (for each 10 mL)	0.79	0.69–0.89	<0.001	0.74	0.62–0.89	<0.001
Core perfusion mismatch (per unit)	0.19	0.06–0.56	<0.001	0.34	0.12–0.97	0.026
Received MT	1.95	0.62–6.07	0.248	1.64	0.48–5.58	0.426
Interaction mismatch group	-	-	0.009	-	-	0.047

aOR, adjusted odds ratio; CI, confidence interval; iv tPA, intravenous tissue plasminogen activator; ICA, internal carotid artery; MT, mechanical thrombectomy.





**Figure 3.** Probability of favourable functional outcome (A) or functional independence (B) by mismatch ratio, in patient receiving mechanical thrombectomy (yellow), and in the control group (blue).



**Figure 4.** Modified Rankin Scale (mRS) distribution in patients receiving mechanical thrombectomy (MT) and those not receiving MT, stratified by core perfusion mismatch ratio (CPMR). IV, intravenous.

**Secondary outcomes**

At 3 months, 54 patients were deceased (31.5% in the MT vs. 30.9% in the control group,  $P=1$ ). Fully adjusted model identi-

fied older age, larger core volume, higher CPMR, and diabetes mellitus as being associated with significantly higher mortality (all  $P<0.01$ ) (Table 2). Treatment group did not influence 3 months mortality rate (Supplementary Tables 2 and 3).

A total of 31 of 161 patients with available data suffered from a sICH (20.6% in the MT group vs. 14.3%,  $P=0.48$ ) (Table 2). In our sample, receiving MT was not associated with higher odds of sICH (aOR, 1.94; 95% CI, 0.6 to 6.26;  $P=0.26$ ). While larger infarct core was associated with more frequent sICH (aOR, 1.01 for each mL increase in core volume; 95% CI, 1 to 1.03;  $P=0.02$ ), higher CPMR was not (Supplementary Tables 4 and 5). In the MT group, substantial recanalization was not associated with decreased odds of sICH ( $P=0.49$ ).

**Discussion**

In this multicenter collaborative study we showed that (1) MT is strongly beneficial on clinical outcome of patients with large infarct core at baseline, and persisting core/penumbral mismatch (CPMR >1.72 in our sample and by extension >1.8), with no heterogeneity in treatment effect across strata of CPMR and (2) that MT does not increase the odds of sICH and mortality.

The question of the best treatment approach for AIS-PVO patients with large infarct at baseline remains unanswered, despite being amongst the most timely and relevant in acute stroke care. There is indeed a critical need to assess treatment opportunities expansion to those patients that were excluded from princeps MT trials (especially patients with LIC, that are at critical risk of poor functional outcomes and for which guidelines remain ambiguous), and may in turn not be offered MT, despite a potential benefit. Until the results of dedicated trials such as Exploration of the limits of mechanical thrombectomy indications in a single action–Large Stroke Therapy Evaluation (IN EXTREMIS–LASTE) or Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window (TENSION) become available, the community faces a challenge in the treatment strategy for this subgroup.

Expectedly, our results are in line with previous studies<sup>3,4,7,19-21</sup> demonstrating the direct correlation between larger infarct core sizes decreased odds of favorable functional outcome. In our sample as a whole, for every 10 mL increase in core volume, there was a 22% increase in the risk of unfavorable outcome, and a 26% increase in the risk of 90 days functional dependence. Our results, in that sense, confirm that presenting with a large infarct at baseline is of poorer prognosis and do support careful expectations' management with families and caregivers.

Less intuitively, but substantiating our working hypothesis, increasing CPMR was also associated with lower chance of favor-

able outcome, with an odd decrease of 81% for every mismatch unit increase. This finding was not unexpected, since patients with higher CPMRS are at inherent higher risk for infarct progression within the hypo-perfused area, until recanalization or if recanalization doesn't occur, or not fast enough. In our sample, the benefit of MT over the control group became significant above a CPMR of 1.72 corresponding to a minimal penumbral volume of 50.4 mL (e.g., if the patient has a core volume of exactly 70 mL) and was stable in the stratified subgroup of patients with CPMRS above 1.7. Although the conceptual framework supporting the benefit of MT in patients with PVO and target mismatch has been substantiated by a large number of publications, including the cornerstone studies from the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) group,<sup>13,22</sup> there is still limited dedicated studies in the specific subgroup of patients with larger infarcts at baseline. Rebello et al.<sup>5</sup> demonstrated in a sample of 24 patients with large infarct cores assessed using CT perfusion (cerebral blood flow <30%; 70 mL) and an penumbra volumes (Tmax >6 seconds) above 40 to 50 mL that MT was associated with significant reduction in final infarct volumes (110±65 mL vs. 319±147 mL,  $P<0.001$ ) but only a nonsignificant improvement in the overall distribution of mRS scores favoring the treatment group ( $P=0.18$ ). These neutral results with regards to clinical outcome, are likely due to insufficient power, in this subgroup limited by a binary design that excluded patients with limited mismatch, precluding to further test interaction between MT effects and CPMR. More recently, Campbell et al.<sup>15</sup> showed in post hoc analyses of individual patient level data from The Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials (HERMES) collaboration, that amongst the 583 patients with computed tomography perfusion (CTP), the interaction between CPMR and endovascular treatment effect was not significant ( $P=0.15$ ), but statistical power was strongly limited by the small number of patients not meeting criteria (less than 5% with a CPMR <1.8 amongst the 583 patients with CTP). In this study, CTP mismatch volume was negatively associated, in univariate analysis, with functional improvement (common odds ratio per 10 mL 0.96; 95% CI, 0.93 to 0.99;  $P=0.009$ ) reinforcing the conceptual balance paradox by which larger mismatch volumes are associated with decreased favorable outcomes due to increased possibilities of infarct progression, and in turn explaining the increasing benefit of MT as CPMR increases, a notion that had not been confirmed before our study in patients with larger infarct cores.

In secondary analyses, we did not show a significant association between MT and the risk of sICH, and there was conversely a positive interaction between infarct core volume and treatment group, in favor of MT. There's been several reports on the risk of sICH after MT in LIC, none of which showed an increase in

the risk of sICH after MT except in the HERMES collaboration<sup>3</sup> where, for patients with ASPECTS 0–4, sICH was more frequent in the MT group, although not significantly (adjusted cOR, 3.94; 95% CI, 0.94 to 16.49;  $P$  interaction=0.025), and not reproduced when restricting the sample to patients with DWI volume  $\geq 70$  mL were no significant difference of sICH between EVT (1/23, 4.3%) and best medical treatment (2/37, 5.4%) was found.<sup>3,15</sup> Of critical note, the most important predictor of sICH and parenchymal hemorrhage is core volume, independent of treatment modality,<sup>3,7,19,20,23</sup> likely explaining that successful reperfusion was associated with lower sICH in many "real life" recent studies.<sup>7,19,20</sup> Whether the benefits of not revascularizing a patient to prevent sICH, outweigh those of revascularization to prevent infarction extension is unknown, but very unlikely, especially in patients with important mismatch, at highest risk for infarct progression and progression to malignant infarction. Our study was neither powered nor designed to answer this question.

There's a long ongoing debate on optimal imaging modality (CT or MRI) for AIS-PVO patients' selection for revascularization strategies.<sup>24–26</sup> The main risk of patients' selection in the context of AIS is over-selection, that is, to decline a patient a treatment that may have been beneficial. For patients with LIC, the question of over-selection is amongst the timeliest in modern stroke care. The first level of over-selection may happen at the core assessment level (e.g., dismissing a patient because of large infarct). Interestingly, in the HERMES collaboration,<sup>3</sup> the treatment benefit in patients with ASPECTs 0–4 derived from the aggregation of CT and MRI ASPECTs data, and was likely contingent on the disproportionately larger effect size seen in the MRI subgroup (aOR, 3.57; 95% CI, 1.22 to 10.39 vs. aOR, 1.68; 95% CI, 0.58 to 4.87 in the CT group). Similarly, Campbell et al.<sup>15</sup> demonstrated that CTP was associated with significantly halved proportion of patients functional independence (OR, 0.47; 95% CI, 0.30 to 0.72;  $P=0.0007$ ), and also with less functional improvement (cOR, 0.51; 95% CI, 0.36 to 0.72;  $P=0.0001$ ) when compared to MRI, both studies reinforcing the notion that MRI may better select patients for MT, but at the inherent risk of overselecting. In that sense, our study provides critical answers with regards to outcome in patients with LIC by the use of MRI with known higher conspicuity and reproducibility to detect and measure infarct core when compared to CT (especially when ASPECTs is used).<sup>27</sup> The second level of over-selection, accounting that patients are considered for MT even with a LIC, is perfusion imaging. Our study showed, using strict post processing method, that patients with a CPMR above 1.72 (and by extension, over 1.8) demonstrated more favorable outcomes when treated with MT but the benefit increase was expectedly linear and not sudden at a discrete threshold of 1.72. While this finding suggests that pa-



tients with lower CPMR are likely to also benefit from MT, more subjects would be needed to demonstrate it, the benefit would likely be lesser, and this would need to be confirmed in a larger scale study. Importantly, we did not demonstrate any harm derived from MT in patients with lower CPMR.

Altogether, by comforting patho-physiologically plausible and statistically stable answers the question of the benefit of MT in patients with LIC at baseline and persisting salvageable tissue, our study raises ethical and philosophical considerations. There is growing evidence that by withholding MT by fear of potential harm for some patients, we may actually dismiss a much larger of patients that may have benefited from revascularization. In that sense, by demonstrating the continuum of unfavorable outcome paralleling the increases in core as well as mismatch volumes, and by showing the increasing benefit of MT with increasing CPMR, we actually fuel the argument that perfusion imaging is not needed as it may delay revascularization in eligible patients (and be used to decline MT to patients with CPMRS in the lower ranges, despite potential benefit). With no evidence of harm from MT in any of the explored configurations in our sample and the above-mentioned continuums in treatment benefit increases, it may be reasonable not to withhold treatment based on strict-cut offs (e.g., the study specific 1.72, applicable only to our sample, or the more common 1.8), but to adjust treatment decisions to both outcome and patients/families' centered expectations. Results from future trials may yield more definite answers to these questions, although the authors are not aware of any ongoing large randomized study using perfusion imaging as a selection criterion in patients with LIC.

Our study has limitations, most inherent to its design. It was a retrospective analysis, with a high risk of selection bias in included cases and important number of excluded cases due to the limited penetration of perfusion imaging for AIS amongst French centers and to the yet unusual use of MT in patients with LIC. For similar reasons, our sample size did not allow for a split into a derivation and a validation cohort, but we aimed at substantiating our estimates by various sensitivity analyses, which proved to be stable. We acknowledge that our control group was biased, by the fact that it included only patients who received intravenous tPA, and that this bias may have yielded underestimated estimates of the benefit of MT over best medical management. Lastly, using CPMR instead of CT allowed for more precise estimates of ischemic infarct cores, but make our results less generalizable beyond the pathophysiological rationale it provides.

## Conclusions

In patients currently deemed ineligible for MT due to large infarct ischemic cores at baseline, CPMR identifies patients strongly benefiting from MT. These findings provide a data-driven framework supporting both the relevance of CPMR perfusion assessment at the acute phase of AIS due to PVO in patients with LIC, and the notion that there is no strict plausible cutoff in core or penumbral volumes above or below which MT may become harmful by comparison to best medical treatment alone. Our results may help at informing the design of future randomized trials and may, further, help inform clinical practice for more individualized decision making in this subgroup until higher level evidence becomes available.

## Supplementary materials

Supplementary materials related to this article can be found online at <https://doi.org/10.5853/jos.2019.02908>.

## Disclosure

The authors have no financial conflicts of interest.

## References

1. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2018;49:e46-e110.
2. Turc G, Bhogal P, Fischer U, Khatri P, Lobotesis K, Mazighi M, et al. European Stroke Organisation (ESO)-European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. *J Neurointerv Surg* 2019;11:535-538.
3. Román LS, Menon BK, Blasco J, Hernández-Pérez M, Dávalos A, Majoie CBLM, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. *Lancet Neurol* 2018;17:895-904.
4. Desilles JP, Consoli A, Redjem H, Coskun O, Ciccio G, Smajda S, et al. Successful reperfusion with mechanical thrombectomy is associated with reduced disability and mortality in patients with pretreatment diffusion-weighted imaging-alberta stroke program early computed tomography score  $\leq 6$ . *Stroke* 2017;48:963-969.
5. Rebello LC, Bouslama M, Haussen DC, Dehkharghani S, Grossberg JA, Belagaje S, et al. Endovascular treatment for patients

- with acute stroke who have a large ischemic core and large mismatch imaging profile. *JAMA Neurol* 2017;74:34–40.
6. Gautheron V, Xie Y, Tisserand M, Raoult H, Soize S, Naggara O, et al. outcome after reperfusion therapies in patients with large baseline diffusion-weighted imaging stroke lesions: a THRACE trial (mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke) subgroup analysis. *Stroke* 2018;49:750–753.
  7. Gilgen MD, Klimek D, Liesirova KT, Meisterernst J, Klinger-Gratz PP, Schroth G, et al. Younger stroke patients with large pretreatment diffusion-weighted imaging lesions may benefit from endovascular treatment. *Stroke* 2015;46:2510–2516.
  8. Mourand I, Abergel E, Mantilla D, Aygnac X, Sacaggiu T, Eker OF, et al. Favorable revascularization therapy in patients with ASPECTS  $\leq 5$  on DWI in anterior circulation stroke. *J Neurointerv Surg* 2018;10:5–9.
  9. Sarraj A, Hassan AE, Savitz S, Sitton C, Grotta J, Chen P, et al. Outcomes of endovascular thrombectomy vs medical management alone in patients with large ischemic cores: a secondary analysis of the optimizing patient's selection for endovascular treatment in acute ischemic stroke (SELECT) study. *JAMA Neurol* 2019;76:1147–1156.
  10. Shih LC, Saver JL, Alger JR, Starkman S, Leary MC, Vinuela F, et al. Perfusion-weighted magnetic resonance imaging thresholds identifying core, irreversibly infarcted tissue. *Stroke* 2003;34:1425–1430.
  11. JENI Research Collaboration. A call for junior interventional neuroradiologists to join the JENI-Research Collaboration. *J Neuroradiol* 2018;45:341–342.
  12. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet* 2007;370:1453–1457.
  13. Lansberg MG, Straka M, Kemp S, Mlynash M, Wechsler LR, Jovin TG, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study. *Lancet Neurol* 2012;11:860–867.
  14. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* 2016;387:1723–1731.
  15. Campbell BCV, Majoie CBLM, Albers GW, Menon BK, Yassi N, Sharma G, et al. Penumbra imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data. *Lancet Neurol* 2019;18:46–55.
  16. Fiorelli M, Bastianello S, von Kummer R, del Zoppo GJ, Larrue V, Lesaffre E, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. *Stroke* 1999;30:2280–2284.
  17. Goyal M, Fargen KM, Turk AS, Mocco J, Liebeskind DS, Frei D, et al. 2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials. *J Neurointerv Surg* 2014;6:83–86.
  18. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: CRC Press, 1994.
  19. Kaesmacher J, Chaloulos-Iakovidis P, Panos L, Mordasini P, Michel P, Hajdu SD, et al. Mechanical thrombectomy in ischemic stroke patients with Alberta stroke program early computed tomography score 0–5. *Stroke* 2019;50:880–888.
  20. Panni P, Gory B, Xie Y, Consoli A, Desilles JP, Mazighi M, et al. Acute stroke with large ischemic core treated by thrombectomy. *Stroke* 2019;50:1164–1171.
  21. Phan K, Saleh S, Dmytriw AA, Maingard J, Barras C, Hirsch JA, et al. Influence of ASPECTS and endovascular thrombectomy in acute ischemic stroke: a meta-analysis. *J Neurointerv Surg* 2019;11:664–669.
  22. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med* 2018;378:708–718.
  23. Marsh EB, Llinas RH, Schneider AL, Hillis AE, Lawrence E, Dziedzic P, et al. Predicting hemorrhagic transformation of acute ischemic stroke: prospective validation of the HeRS score. *Medicine (Baltimore)* 2016;95:e2430.
  24. Albers GW. Endovascular thrombectomy in patients with large infarctions: reasons for restraint. *Lancet Neurol* 2018;17:836–837.
  25. Kim JT, Cho BH, Choi KH, Park MS, Kim BJ, Park JM, et al. Magnetic resonance imaging versus computed tomography angiography based selection for endovascular therapy in patients with acute ischemic stroke. *Stroke* 2019;50:365–372.
  26. Provost C, Soudant M, Legrand L, Ben Hassen W, Xie Y, Soize S, et al. Magnetic resonance imaging or computed tomography before treatment in acute ischemic stroke. *Stroke* 2019;50:659–664.
  27. Farzin B, Fahed R, Guilbert F, Poppe AY, Daneault N, Durocher AP, et al. Early CT changes in patients admitted for thrombectomy: intrarater and interrater agreement. *Neurology* 2016;87:249–256.

**Supplementary Table 1.** Univariate analysis of outcome predictors (mRS 0–3)

Variable	Unfavorable (n=99)	Favorable (n=73)	P
Age (yr)	72.9±14.2	63.8±15.5	<0.001
Female sex	36 (36.4)	26 (35.6)	1
Dyslipidemia	49 (49.5)	20 (27.4)	0.003
Diabetes mellitus	20 (20.2)	6 (8.2)	0.005
Tobacco use (current or past)	28 (28.3)	28 (38.4)	0.187
Hypertension	65 (65.7)	32 (43.8)	0.005
NIHSS	19.3±4.5	17.5±4.3	0.011
Left sided stroke	46 (46.5)	29 (39.7)	0.355
iv tPA	56 (56.6)	49 (67.1)	0.205
Drip and ship	22 (22.2)	11 (15.1)	0.327
ICA occlusion	21 (21.2)	11 (15.1)	0.329
Delay till imaging (min)	167.3±137.9	153.1±116.4	0.468
Volume T max <6 sec (mL)	185.1±68	154.7±68.4	0.004
Mismatch ratio	1.8±0.7	1.7±0.6	0.166
Core volume (mL)	108.4±41.7	94±26.6	<0.001
Received MT	74 (74.7)	56 (76.7)	0.851

Values are presented as mean±standard deviation or number (%).

mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; iv tPA, intravenous tissue plasminogen activator; ICA, internal carotid artery; MT, mechanical thrombectomy.

**Supplementary Table 2.** Univariable analysis of 90-day mortality

Variable	Dead (n= 54)	Alive (n=118)	P
Age (yr)	77.63±11.99	65.09±15.21	<0.001
Female sex	19 (35.2)	43 (36.4)	1
Dyslipidemia	27 (50)	42 (35.6)	0.094
Diabetes	15 (27.8)	11 (9.3)	0.003
Hypertension	37 (68.5)	60 (50.8)	0.033
NIHSS	19.78±4.7	17.96±4.25	0.019
Tobacco use	11 (20.4)	45 (38.1)	0.023
ICA occlusion	10 (18.5)	22 (18.6)	1.000
Delay till imaging (min)	164.87±155.96	159.61±115.33	0.825
Drip and ship	12 (22.2)	21 (17.8)	0.534
iv tPA	30 (55.6)	75 (63.6)	0.401
Volume core (mL)	111.3±43.4	98.11±32.49	0.025
Volume T max >6 sec (min)	192.02±64.11	163.13±70.38	0.009
Mismatch ratio	1.86±0.75	1.7±0.65	0.173
MT	41 (31.5)	89 (68.5)	vs. control, 1.000
Control	13 (30.9)	29 (69.1)	

Values are presented as number (%) or mean±standard deviation.

NIHSS, National Institute of Health Stroke Scale; ICA, internal carotid artery; iv tPA, intravenous tissue plasminogen activator; MT, mechanical thrombectomy.

**Supplementary Table 3.** Multivariable model of 90-day mortality predictors (pre specified adjustment for core volume, mismatch ratio, and treatment group)

Variable	aOR	95% CI	P
Age	1.11	1.07–1.16	<0.001
Diabetes	4.34	1.54–12.27	0.006
Volume core (each 10 mL)	1.32	1.16–1.53	<0.001
Core perfusion mismatch	2.38	1.26–4.47	0.006
MT vs. Control	0.49	0.19–1.37	0.177

aOR, adjusted odds ratio; CI, confidence interval; MT, mechanical thrombectomy.

**Supplementary Table 4.** Univariable analysis of sICH (ECASS II) predictors

Variable	sICH (n=31)	No sICH (n=130)	P
Age (yr)	72.89±12.15	67.74±15.98	0.051
Female sex	9 (29.0)	50 (38.5)	0.409
Dyslipidemia	12 (38.7)	51 (39.2)	1.000
Diabetes mellitus	9 (29.0)	14 (10.8)	0.002
Hypertension	22 (71.0)	67 (51.5)	0.068
NIHSS	18.53±3.46	18.6±4.67	0.925
Tobacco use	6 (19.4)	45 (34.6)	0.133
ICA occlusion	7 (22.6)	22 (16.9)	0.444
Delay till imaging (min)	149.71±113.66	163.7±131.43	0.548
Drip and ship	7 (22.6)	24 (18.5)	0.609
iv tPA	19 (61.3)	78 (60.0)	1.000
Volume core (mL)	112.43±38.47	100.6±35.67	0.126
Volume T max >6 sec (mL)	188.75±59.87	171.58±72.5	0.175
Mismatch ratio	1.8±0.72	1.76±0.7	0.795
MT (P for vs. control)	26 (20.6)	100 (76.4)	0.475
Control	5 (14.3)	30 (85.7)	


Values are presented as number (%) or mean±standard deviation.

sICH, symptomatic intracerebral hemorrhage; ECASS, European Cooperative Acute Stroke Study; NIHSS, National Institute of Health Stroke Scale; ICA, internal carotid artery; iv tPA, intravenous tissue plasminogen activator; MT, mechanical thrombectomy.

**Supplementary Table 5.** Multivariable model of symptomatic intra-cranial hemorrhage predictors (pre specified adjustment for core volume, mismatch ratio and treatment group)

Variable	aOR	95% CI	P
Age (yr)	1.03	1.00–1.07	0.051
Hypertension	1.15	0.43–3.03	0.77
Diabetes	3.58	1.21–10.64	0.02
Volume core (each 10 mL)	1.01	1.00–1.03	0.02
Core perfusion mismatch	1.29	0.68–2.46	0.43
MT vs. Control	1.94	0.59–6.26	0.26

aOR, adjusted odds ratio; CI, confidence interval; MT, mechanical thrombectomy.



**Supplementary Figure 1.** Distribution of core perfusion mismatch ratios (CPMRs) in the entire sample (A) and proportion of patients with CPMRs above 1.6, 1.8, and 2 (B).